Did you have any side effects with this medicine?

 No   Yes 

• Chloramphenicol (Mycogynax) indications
• Uses of Chloramphenicol (Mycogynax) in details
• Chloramphenicol (Mycogynax) description
• Chloramphenicol (Mycogynax) dosage
• Chloramphenicol (Mycogynax) interactions
• Chloramphenicol (Mycogynax) side effects
• Chloramphenicol (Mycogynax) contraindications
• Dexamethasone (Mycogynax) indications
• Uses of Dexamethasone (Mycogynax) in details
• Dexamethasone (Mycogynax) description
• Dexamethasone (Mycogynax) dosage
• Dexamethasone (Mycogynax) interactions
• Dexamethasone (Mycogynax) side effects
• Dexamethasone (Mycogynax) contraindications
• Metronidazole (Mycogynax) indications
• Uses of Metronidazole (Mycogynax) in details
• Metronidazole (Mycogynax) description
• Metronidazole (Mycogynax) dosage
• Metronidazole (Mycogynax) interactions
• Metronidazole (Mycogynax) side effects
• Metronidazole (Mycogynax) contraindications
• Nystatin (Mycogynax) indications
• Uses of Nystatin (Mycogynax) in details
• Nystatin (Mycogynax) description
• Nystatin (Mycogynax) dosage
• Nystatin (Mycogynax) interactions
• Nystatin (Mycogynax) side effects
• Nystatin (Mycogynax) contraindications

Consists of Chloramphenicol, Dexamethasone, Metronidazole, Nystatin

What is Chloramphenicol (Mycogynax)?

Chloramphenicol (Mycogynax) belongs to the family of medicines called antibiotics. Chloramphenicol (Mycogynax) ophthalmic preparations are used to treat infections of the eye. Chloramphenicol (Mycogynax) may be given alone or with other medicines that are taken by mouth for eye infections.

Chloramphenicol (Mycogynax) is available only with your doctor's prescription.

Chloramphenicol (Mycogynax) indications

Chloramphenicol (Mycogynax) should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to Chloramphenicol (Mycogynax).

Chloramphenicol (Mycogynax), 1% (Chloramphenicol (Mycogynax) Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by Chloramphenicol (Mycogynax)-susceptible organisms.

The particular antiinfective drug in this product is active against the following common bacterial eye pathogens:

Staphylococcus aureus

Streptococcus, including Streptococcus pneumoniae

Escherichia coli

Haemophilus influenzae

Klebsiella/Enterobacter species

Moraxella lucunata

(Morax-Axenfeld bacillus)

Neisseria species

This product does not provide adequate coverage against:

Pseudomonas aeruginosa

Serratia marcescens

How should I use Chloramphenicol (Mycogynax)?

Use Chloramphenicol (Mycogynax) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Chloramphenicol (Mycogynax) is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Chloramphenicol (Mycogynax) at home, carefully follow the injection procedures taught to you by your health care provider.
• If Chloramphenicol (Mycogynax) contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.
• To clear up your infection completely, continue using Chloramphenicol (Mycogynax) for the full course of treatment even if you feel better in a few days.
• Keep this product, as well as syringes and needles, out of the reach of children. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.
• If you miss a dose of Chloramphenicol (Mycogynax), use it as soon as possible. Then use your doses at evenly spaced times as directed by your doctor. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Chloramphenicol (Mycogynax).

Uses of Chloramphenicol (Mycogynax) in details

Use: Labeled Indications

Serious infections: Treatment of serious infections, including cystic fibrosis exacerbations, bacterial meningitis, and bacteremia, caused by Chlamydiaceae, Haemophilus influenzae, Rickettsia, Salmonella spp. (acute infections), and other organisms when other less toxic agents are ineffective or contraindicated.

Guideline recommendations: Chloramphenicol (Mycogynax) may be considered for use as an alternative agent to doxycycline in the treatment of tickborne rickettsial diseases (eg, Rocky Mountain spotted fever [RMSF]); however, epidemiologic studies suggest that Chloramphenicol (Mycogynax)-treated patients with RMSF are at a higher risk of death compared to tetracycline-treated patients. In addition, Chloramphenicol (Mycogynax) is not effective in the treatment of human ehrlichiosis or anaplasmosis, therefore, use with caution in the empiric treatment of tickborne rickettsial diseases (CDC [Biggs 2016]).

Chloramphenicol (Mycogynax) description

Each 100 g contains Chloramphenicol (Mycogynax) 1 g.

Chloramphenicol (Mycogynax) dosage

Chloramphenicol (Mycogynax) Dosage

Generic name: Chloramphenicol (Mycogynax)

Dosage form: ophthalmic ointment

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

A small amount of ointment placed in the lower conjunctival sac every three hours, or more frequently if deemed advisable by the prescribing physician. Administration should be continued day and night the first 48 hours, after which the interval between applications may be increased. Treatment should be continued for at least 48 hours after the eye appears normal.

More about Chloromycetin Ophthalmic (Chloramphenicol (Mycogynax) ophthalmic)

• Side Effects
• Breastfeeding
• Dosage Information
• Drug Interactions
• Support Group
• 0 Reviews · Be the first to review/rate this drug

Consumer resources

• Other brands: Ocu-Chlor, Chloroptic, AK-Chlor

Professional resources

• Chloramphenicol (Mycogynax) (FDA)

Other formulations

• Chloromycetin
• Chloromycetin Sodium Succinate

Chloramphenicol (Mycogynax) interactions

Alcohol (Ethyl): Chloramphenicol (Mycogynax) (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). Monitor therapy

Barbiturates: Chloramphenicol (Mycogynax) (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Mycogynax) (Systemic). Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

Carbocisteine: Chloramphenicol (Mycogynax) (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, Chloramphenicol (Mycogynax) may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. Monitor therapy

CefTAZidime: Chloramphenicol (Mycogynax) (Systemic) may diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Consider therapy modification

Chloramphenicol (Mycogynax) (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination

Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Avoid combination

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy

CycloSPORINE (Systemic): Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent Chloramphenicol (Mycogynax). Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of Chloramphenicol (Mycogynax). Consider therapy modification

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Consider therapy modification

Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination

Fosphenytoin: May decrease the serum concentration of Chloramphenicol (Mycogynax) (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Mycogynax) (Systemic). Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of Fosphenytoin. Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

Mesalamine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy

Phenytoin: May decrease the serum concentration of Chloramphenicol (Mycogynax) (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Mycogynax) (Systemic). Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of Phenytoin. Monitor therapy

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy

RifAMPin: May increase the metabolism of Chloramphenicol (Mycogynax) (Systemic). Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

Sulfonylureas: Chloramphenicol (Mycogynax) (Systemic) may decrease the metabolism of Sulfonylureas. Monitor therapy

Tacrolimus (Systemic): Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent Chloramphenicol (Mycogynax). Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of Chloramphenicol (Mycogynax). Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification

Vitamin B12: Chloramphenicol (Mycogynax) (Systemic) may diminish the therapeutic effect of Vitamin B12. Monitor therapy

Vitamin K Antagonists (eg, warfarin): Chloramphenicol (Mycogynax) (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of Vitamin K Antagonists. Monitor therapy

Voriconazole: Chloramphenicol (Mycogynax) (Systemic) may increase the serum concentration of Voriconazole. Monitor therapy

Chloramphenicol (Mycogynax) side effects

See also:
What are the possible side effects of Chloramphenicol (Mycogynax)?

Applies to Chloramphenicol (Mycogynax): capsule, powder for solution, suspension

In addition to its needed effects, some unwanted effects may be caused by Chloramphenicol (Mycogynax) (the active ingredient contained in Chloramphenicol (Mycogynax)). In the event that any of these side effects do occur, they may require medical attention.

Stop taking Chloramphenicol (Mycogynax) and get emergency help immediately if any of the following effects occur:

Rare - in babies only

• Bloated stomach
• drowsiness
• gray skin color
• low body temperature
• uneven breathing
• unresponsiveness

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking Chloramphenicol (Mycogynax):

Less common:

• Pale skin
• sore throat and fever
• unusual bleeding or bruising
• unusual tiredness or weakness (the above side effects may also occur up to weeks or months after you Stop taking Chloramphenicol (Mycogynax))

• Confusion, delirium, or headache
• eye pain, blurred vision, or loss of vision
• numbness, tingling, burning pain, or weakness in the hands or feet
• skin rash, fever, or difficulty in breathing

Minor Side Effects

Some of the side effects that can occur with Chloramphenicol (Mycogynax) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common:

• Diarrhea
• nausea or vomiting

Chloramphenicol (Mycogynax) contraindications

See also:
What is the most important information I should know about Chloramphenicol (Mycogynax)?

Chloramphenicol (Mycogynax) Lotion is contraindicated for premature neonates because their skin may be more permeable than full term infants and their liver enzymes may not be sufficiently developed. It is also contraindicated for patients with Norwegian (crusted) scabies due to possible increased absorption. It is also contraindicated for patients with known seizure disorders and for individuals with a known sensitivity to the product or any of its components.

What is Dexamethasone (Mycogynax)?

Dexamethasone (Mycogynax) intravitreal implant is used to treat an eye disease called macular edema (swelling of the back of the eye). Macular edema occurs when a blood vessel in the eye is clogged. This causes vision changes that must be treated right away. Dexamethasone (Mycogynax) is a corticosteroid (steroid medicine) that helps reduce the swelling in the eye.

Dexamethasone (Mycogynax) intravitreal implant is also used to treat an eye disease called uveitis (swelling in the middle part of the eye). Dexamethasone (Mycogynax) is also used to treat diabetic macular edema in patients with artificial lens implant or are scheduled for cataract surgery.

Dexamethasone (Mycogynax) is to be given only by or under the supervision of your doctor.

Dexamethasone (Mycogynax) indications

Retinal Vein Occlusion

Dexamethasone (Mycogynax)® (Dexamethasone (Mycogynax) intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Posterior Segment Uveitis

Dexamethasone (Mycogynax)® is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

​1.3 Diabetic Macular Edema

​Dexamethasone (Mycogynax)® is indicated for the treatment of diabetic macular edema.

How should I use Dexamethasone (Mycogynax)?

Use Dexamethasone (Mycogynax) suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• If your doctor prescribed more than 1 eye medicine, find out the best order for using each medicine.
• Remove contact lenses before using Dexamethasone (Mycogynax) suspension.
• Shake well before each use.
• To use Dexamethasone (Mycogynax) suspension in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
• To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
• If you miss a dose of Dexamethasone (Mycogynax) suspension, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Dexamethasone (Mycogynax) suspension.

Uses of Dexamethasone (Mycogynax) in details

This medication is used to treat various conditions such as severe allergic reactions, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, and skin diseases. It is also used to test for an adrenal gland disorder (Cushing's syndrome). It decreases your body's natural defensive response and reduces symptoms such as swelling and allergic-type reactions. Dexamethasone (Mycogynax) is a corticosteroid hormone (glucocorticoid). This injectable form of Dexamethasone (Mycogynax) is used when a similar drug cannot be taken by mouth or when a very fast response is needed, especially in patients with severe medical conditions. Talk to your doctor about the risks and benefits of Dexamethasone (Mycogynax), especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.

This drug may also be used with other medications as a replacement for certain hormones.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This drug may also be used to prevent nausea and vomiting caused by cancer chemotherapy.

How to use Dexamethasone (Mycogynax) injection

This medication is given by injection into a vein, muscle, joint, or skin wound as directed by your doctor. Follow your doctor's directions carefully. Dosage is based on your medical condition and response to treatment. Do not increase your dose or use this drug more often than prescribed without consulting your doctor. Some patients (especially newborns) should receive the preservative-free form of this drug. In these patients, when mixing this form of the drug, be sure to use IV fluid that is also preservative-free. Use these mixtures within 24 hours.

If this medication is injected into a joint, be careful how much pressure you put on that joint, even if it is feeling better. Ask your doctor how much you can move/use the joint while it is healing.

If you have been using this medication for a long time, do not suddenly stop using it without your doctor's approval. Your dose may need to be gradually decreased to reduce symptoms such as weakness, weight loss, nausea, or extreme tiredness.

If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.

Tell your doctor if your condition persists or worsens.

Dexamethasone (Mycogynax) description

Dexamethasone (Mycogynax) is an intravitreal implant containing 0.7 mg (700 μg) Dexamethasone (Mycogynax) in the Dexamethasone (Mycogynax) solid polymer drug delivery system. Dexamethasone (Mycogynax) is preloaded into a single-use, specially designed DDS applicator to facilitate injection of the rod-shaped implant directly into the vitreous.

The Dexamethasone (Mycogynax) system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix. Dexamethasone (Mycogynax) is preservative-free. The chemical name for Dexamethasone (Mycogynax) is pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydoxy-16-methyl-,(11β, 16α). Its molecular weight is 392.47; molecular formula: C₂₂H₂₉FO₃.

Dexamethasone (Mycogynax) occurs as a white to cream-colored crystalline powder having not more than a slight odor, and is practically insoluble in water and very soluble in alcohol.

The PLGA matrix slowly degrades to lactic acid and glycolic acid.

Dexamethasone (Mycogynax) dosage

Dexamethasone (Mycogynax) Dosage

Generic name: Dexamethasone (Mycogynax) 20mg

Dosage form: tablets

Medically reviewed by Drugs.com. Last updated on Oct 17, 2019.

• Side Effects
• Dosage
• Professional
• Interactions
• Pregnancy
• More

2.1 Recommended Dosage

The recommended dosage of Dexamethasone (Mycogynax) is 20 mg or 40 mg, orally, once daily, on specific days depending on the treatment regimen. Refer to the Prescribing Information of the other anti-myeloma products used in combination with Dexamethasone (Mycogynax) for specific Dexamethasone (Mycogynax) dosing. Dexamethasone (Mycogynax) can be administered with or without food.

Dose Modification for Elderly Patients

Dose-reduction for Dexamethasone (Mycogynax) is recommended for elderly patients, due to increased toxicity in these patients. Refer to the Prescribing Information of the other anti-myeloma products used as part of a combination regimen with Dexamethasone (Mycogynax), for dosing recommendations in elderly patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

• Can I use expired neomycin and polymyxin b sulfates, Dexamethasone (Mycogynax) ophthalmic?

Medical Disclaimer

More about Dexamethasone (Mycogynax) (Dexamethasone (Mycogynax))

• Side Effects
• During Pregnancy or Breastfeeding
• Imprints, Shape & Color Data
• Drug Interactions
• Drug class: glucocorticoids
• FDA Alerts (7)

Consumer resources

Other brands: Dexamethasone (Mycogynax), Dexamethasone (Mycogynax) Intensol, Dexasone, Baycadron,... +8 more

Professional resources

• Dexamethasone (Mycogynax) (FDA)
• ... +1 more

Related treatment guides

• Multiple Myeloma

Dexamethasone (Mycogynax) interactions

See also:
What other drugs will affect Dexamethasone (Mycogynax)?

Tablet/Forte Tablet: Barbiturates, Phenytoin, Ephedrine, Carbamazepine, Rifampicin and Other Drugs that Stimulate Hepatic Metabolism: May lessen the effect of Dexamethasone (Mycogynax) due to enhancement of Dexamethasone (Mycogynax) metabolism. Increase in Dexamethasone (Mycogynax) dosage may be required.

CYP3A4 Inhibitors eg, Ketoconazole and Macrolide Antibiotics: May increase plasma concentrations of corticosteroids.

Indinavir, Erythromycin and Other Drugs Metabolized by CYP3A4: Dexamethasone (Mycogynax) is a moderate inducer of CYP3A4 and may increase clearance of these drugs, resulting in decreased plasma concentrations.

Oral Contraceptives and Estrogen:

Aspirin: Concomitant use of aspirin or other nonsteroidal anti-inflammatory agents (NSAIDs) and corticosteroids increases the risk of gastrointestinal adverse effects. Use aspirin cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Concomitant administration of Dexamethasone (Mycogynax) and aspirin may also cause changes in salicylate plasma protein-binding and its rate of metabolism. These changes cause lowering of plasma salicylate levels.

Warfarin: Co-administration of corticosteroids and warfarin usually results in decreased response to warfarin, although there have been conflicting results.

Monitor coagulation indices frequently to maintain the desired anticoagulant effect.

Potassium-Depleting Agents eg, Diuretics and Amphotericin-B: Observe patients closely for the development of hypokalemia. Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

Anticholinesterase Agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agents at least 24 hrs before initiating corticosteroid therapy.

Antacids: Large doses of antacids cause alteration in corticosteroid absorption.

Insulin: Concomitant administration of Dexamethasone (Mycogynax) and insulin generally requires higher doses of insulin.

Ketoconazole: Decreases the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.

Thalidomide: Toxic epidermal necrolysis has been reported when Dexamethasone (Mycogynax) was used concomitantly with thalidomide.

Indomethacin: May cause false negative results in the Dexamethasone (Mycogynax) suppression test (DST).

Other Interactions: Toxoids and Live or Inactivated Vaccines: Patients on prolonged corticosteroid therapy may exhibit diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.

Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. If possible, postpone routine administration of vaccines or toxoids until corticosteroid therapy is discontinued.

Antidiabetic Agents: Dosage adjustment of antidiabetic agents may be required because corticosteroids may increase blood glucose concentrations.

Skin Tests: Corticosteroids may suppress reactions to skin tests.

Dexamethasone (Mycogynax) side effects

See also:
What are the possible side effects of Dexamethasone (Mycogynax)?

Clinical Studies Experience: Treatment of Macular Edema: Clinical Studies 206207‐008 and 206207‐009 (Initial 6‐month Treatment Period): The clinical safety of Dexamethasone (Mycogynax) was assessed in 2 phase 3 randomized, double‐masked, sham-controlled studies in patients with macular edema following BRVO or CRVO. In both studies, a total of 421 patients were randomized and received Dexamethasone (Mycogynax) and 423 received sham.

The most frequently reported adverse reactions considered to be related to the intravitreal injection procedure rather than the Dexamethasone (Mycogynax) implant, included vitreous hemorrhage and conjunctival edema.

Intraocular Pressure in the Initial 6‐month Treatment Period of Studies 008 and 009: See Table 4.

The proportion of patients with increases from baseline IOP ≥10 mmHg in the study eye was significantly greater with Dexamethasone (Mycogynax) compared to sham at days 7, 30, 60, and 90. At day 180, there were no significant differences between Dexamethasone (Mycogynax) and sham.

The proportion of patients experiencing increased IOP with Dexamethasone (Mycogynax) peaked at day 60 and returned to baseline levels by day 180. Elevations of IOP either did not require treatment or were managed with topical IOP‐lowering medications in the vast majority of patients. During the initial treatment period, only 0.7% (3/421) of the patients who received Dexamethasone (Mycogynax) required laser or surgical procedures for management of elevated IOP in the study eye compared with 0.2% (1/423) with sham.

Systemic effects with Dexamethasone (Mycogynax) would be expected to be negligible due to low systemic levels (below the lower level of quantitation). The adverse event profile for BRVO patients was generally similar to that observed for CRVO patients, and to the overall population. The overall incidence of adverse events was higher for the subgroup of patients with CRVO, which is consistent with the nature of the disease as patients with CRVO are more likely to develop ocular adverse events than patients with BRVO, even when not treated.

Clinical Studies 206207‐008 and 206207‐009 (6‐month Open‐label Extension): The clinical safety of Dexamethasone (Mycogynax) was further assessed in a 6‐month open‐label (OL) extension of both phase 3 studies. Patients were eligible for re‐treatment if the BCVA was <84 letters or retinal thickness was >250 mcg in the central 1 mm macular subfield and the investigator considered that the procedure would not put the patient at significant risk. The re‐treated population consisted of patients who received Dexamethasone (Mycogynax), or sham as their 1st injection, completed the initial treatment period at day 180, and then received Dexamethasone (Mycogynax) as their 2nd injection. A total of 997 patients received the Dexamethasone (Mycogynax) injection in the open‐label phase of both studies.

For those events reported at a rate of ≥1%, the types of events and their incidence following the 2nd injection were similar to those seen following the 1st injection with the exception of subcapsular cataract which were higher in patients who had received Dexamethasone (Mycogynax) as their 1st injection followed by Dexamethasone (Mycogynax) as the 2nd injection. More specifically, subcapsular cataracts in the study eye were notably more common in the Dexamethasone (Mycogynax)/Dexamethasone (Mycogynax) group (12.9%) compared to either sham/Dexamethasone (Mycogynax) (3.4%).

For events reported in ≤1% of patients, mostly in only 1 or 2 patients per group, some differences between the 1st and 2nd injection were seen. Review of these differences does not suggest a safety signal associated with repeat treatments.

The incidence of IOP increased was comparable between patients receiving either 1 or 2 doses of Dexamethasone (Mycogynax).

Treatment of Uveitis: Clinical Study 206207‐014: The clinical safety of Dexamethasone (Mycogynax) was assessed in a multicenter, masked, and randomized, 26‐week phase 3 study in the treatment of non‐infectious uveitis affecting the posterior segment of the eye. A total of 76 patients were treated with Dexamethasone (Mycogynax) and 75 were treated with sham.

Intraocular Pressure in Study ‐014: As shown in Table 7, there were no clinically meaningful differences in the proportions of Dexamethasone (Mycogynax) and sham patients who experienced IOP at ≥25 mmHg or ≥35 mmHg in the study eye, at any visit. At week 26, no Dexamethasone (Mycogynax) patients and 3 sham patients had an IOP ≥25 mmHg; no patients had an IOP ≥35 mmHg.

Table 8 shows the proportion of patients with increases from baseline IOP ≥10 mmHg in the study eye was similar between Dexamethasone (Mycogynax) and sham, except at week 8 where significantly higher percentages were observed with Dexamethasone (Mycogynax) (9.6%) compared to sham (0%), p=0.013. At week 26, only 1 Dexamethasone (Mycogynax) patient and 2 sham patients showed an increase from baseline IOP ≥10 mmHg.

The proportion of Dexamethasone (Mycogynax)‐treated patients with increased IOP (≥25 mmHg) peaked at week 3 and returned to baseline by week 26. During the treatment period, no patients required incisional surgery for glaucoma. Three patients required laser iridotomies in the study eye for the treatment of pupillary block, iris bombe, and raised IOP.

Post-Marketing Experience: The following adverse reactions have been identified during post-marketing use of Dexamethasone (Mycogynax) in clinical practice. Because post-marketing reporting of these reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions. The reactions have been chosen for inclusion due to a combination of the frequency of reporting and/or possible causal connection to Dexamethasone (Mycogynax).

Eye Disorders: Endophthalmitis: Hypotony of eye (associated with vitreous leakage due to injection), retinal detachment.

General Disorders and Administration Site Conditions: Complication of device insertion (implant misplacement), device dislocation with or without corneal edema.

Dexamethasone (Mycogynax) contraindications

See also:
What is the most important information I should know about Dexamethasone (Mycogynax)?

You should not use this medication if you are allergic to Dexamethasone (Mycogynax), or if you have a fungal infection anywhere in your body.

Before taking Dexamethasone (Mycogynax), tell your doctor about all of your medical conditions, and about all other medicines you are using. There are many other diseases that can be affected by steroid use, and many other medicines that can interact with steroids.

Your steroid medication needs may change if you have any unusual stress such as a serious illness, fever or infection, or if you have surgery or a medical emergency. Tell your doctor about any such situation that affects you during treatment.

Steroid medication can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had. Tell your doctor about any illness or infection you have had within the past several weeks.

Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.

Do not receive a "live" vaccine while you are taking Dexamethasone (Mycogynax). Vaccines may not work as well while you are taking a steroid.

Do not stop using Dexamethasone (Mycogynax) suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication.

Wear a medical alert tag or carry an ID card stating that you take Dexamethasone (Mycogynax). Any medical care provider who treats you should know that you are using a steroid.

What is Metronidazole (Mycogynax)?

Metronidazole (Mycogynax) is used to treat bacterial infections in different areas of the body. The extended-release tablets are used to treat women with vaginal infections (bacterial vaginosis).

Metronidazole (Mycogynax) belongs to the class of medicines known as antibiotics. It works by killing bacteria or preventing their growth. However, Metronidazole (Mycogynax) will not work for colds, flu, or other virus infections.

Metronidazole (Mycogynax) is available only with your doctor's prescription.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Metronidazole (Mycogynax) is used in certain patients with the following medical conditions:

• Clostridium difficile diarrhea or colitis (antibiotic-associated colitis).
• Crohn's disease (inflammatory bowel disease).
• Gastritis or stomach ulcers due to Helicobacter pylori.
• Giardiasis (parasite infection in the intestines).

Metronidazole (Mycogynax) indications

Symptomatic Trichomoniasis. Metronidazole (Mycogynax) USP 375 mg are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).

Asymptomatic Trichomoniasis. Metronidazole (Mycogynax) USP 375 mg are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.

Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with Metronidazole (Mycogynax) in cases of reinfection.

Amebiasis. Metronidazole (Mycogynax) USP 375 mg are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.

In amebic liver abscess, Metronidazole (Mycogynax) USP 375 mg therapy does not obviate the need for aspiration or drainage of pus.

Anaerobic Bacterial Infections. Metronidazole (Mycogynax) USP 375 mg are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole (Mycogynax) therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole (Mycogynax) USP 375 mg.

INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, or Peptostreptococcus species.

SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, or Fusobacterium species.

GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, or Fusobacterium species.

BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group or Clostridium species.

BONE AND JOINT INFECTIONS (as adjunctive therapy) caused by Bacteroides species including the B. fragilis group.

CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group.

LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.

ENDOCARDITIS caused by Bacteroides species including the B. fragilis group.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole (Mycogynax) USP 375 mg and other antibacterial drugs, Metronidazole (Mycogynax) USP 375 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

How should I use Metronidazole (Mycogynax)?

Use Metronidazole (Mycogynax) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Wash and completely dry the affected area. Be sure the area is completely dry before applying Metronidazole (Mycogynax).
• Apply a thin layer of Metronidazole (Mycogynax) to the affected area. Gently rub the medicine in until it is evenly distributed.
• Wash your hands immediately after using Metronidazole (Mycogynax).
• You may apply cosmetics after you use Metronidazole (Mycogynax). If you are using the lotion, wait 5 minutes after you use Metronidazole (Mycogynax) before you apply cosmetics so that the lotion has time to dry.
• Use Metronidazole (Mycogynax) on a regular schedule to get the most benefit from it. Using it at the same time(s) each day will help you remember to use it.
• Continue to use Metronidazole (Mycogynax) even if your condition improves, unless a doctor tells you otherwise. Do not miss any doses.
• If you miss a dose of Metronidazole (Mycogynax), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Metronidazole (Mycogynax).

Uses of Metronidazole (Mycogynax) in details

Metronidazole (Mycogynax) is an antibiotic that is used to treat a wide variety of infections. It works by stopping the growth of certain bacteria and parasites.

This antibiotic treats only certain bacterial and parasitic infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Metronidazole (Mycogynax) may also be used with other medications to treat certain stomach/intestinal ulcers caused by a bacteria (H. pylori).

How to use Metronidazole (Mycogynax)

Take this medication by mouth as directed by your doctor. To prevent stomach upset, take this medication with food or a full glass of water or milk. The dosage is based on your medical condition and response to treatment.

Antibiotics work best when the amount of medicine in your body is kept at a constant level. Take this drug at evenly spaced intervals.

Continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.

Tell your doctor if your condition lasts or gets worse.

Metronidazole (Mycogynax) description

Each 100 mL contains Metronidazole (Mycogynax) USP 500 mg, sodium chloride USP 0.72% w/v, water for injection USP as needed.

Metronidazole (Mycogynax) injection, USP is a parenteral dosage form of the synthetic antibacterial agent 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole. The empirical formula is C₆H₉N₃O₃ and the molecular weight is 171.15.

Metronidazole (Mycogynax) injection, USP in 100 mL is a sterile, nonpyrogenic, iso-osmotic, buffered solution of 500 mg Metronidazole (Mycogynax), USP, 790 mg sodium chloride, USP, 47.6 mg dried dibasic sodium phosphate, USP and 22.9 mg anhydrous citric acid, USP. Metronidazole (Mycogynax) injection, USP has an osmolarity of 310 mOsmol/L (calc) and a pH of 5.5 (4.5 to 7).

Metronidazole (Mycogynax) dosage

Metronidazole (Mycogynax) Dosage

Generic name: Metronidazole (Mycogynax) 750mg

Dosage form: tablet, film coated, extended release

See also:

• Metronidazole (Mycogynax) tablet, film coated
• Metronidazole (Mycogynax) Capsules capsule
• Metronidazole (Mycogynax) Injection injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Bacterial Vaginosis

750 mg once daily by mouth for seven consecutive days.

Metronidazole (Mycogynax) 750 mg tablets should be taken under fasting conditions, at least one hour before or two hours after meals. The optimum extended-release characteristics of Metronidazole (Mycogynax) 750 mg are obtained when the drug is taken under fasting conditions.

Metronidazole (Mycogynax) tablets should not be split, chewed, or crushed.

Dosage Adjustments

Patients Undergoing Hemodialysis

Hemodialysis removes significant amounts of Metronidazole (Mycogynax) and its metabolites from systemic circulation. The clearance of Metronidazole (Mycogynax) will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of Metronidazole (Mycogynax) cannot be separated from a hemodialysis session, supplementation of Metronidazole (Mycogynax) dosage following the hemodialysis session should be considered, depending on the patient's clinical situation.

More about Metronidazole (Mycogynax) (Metronidazole (Mycogynax))

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 6 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Metronidazole (Mycogynax) extended-release tablets
• Metronidazole (Mycogynax)
• Metronidazole (Mycogynax) (Advanced Reading)

• Other brands: Metro

Professional resources

• Metronidazole (Mycogynax) (FDA)
• Metronidazole (Mycogynax) Hydrochloride (AHFS Monograph)

Other formulations

• Metronidazole (Mycogynax)
• Metronidazole (Mycogynax) IV
• Metronidazole (Mycogynax)

Related treatment guides

• Bacterial Vaginitis
• Balantidium coli
• Dientamoeba fragilis
• Nongonococcal Urethritis
• STD Prophylaxis

Metronidazole (Mycogynax) interactions

See also:
What other drugs will affect Metronidazole (Mycogynax)?

Simultaneous administration of Zol with: